Browsing Tag
Opdivo Qvantig
2 posts
NHS adopts 60-second Keytruda jab as Merck races to convert 14,000 UK patients before biosimilars hit
Merck's Keytruda patent expires in 2028. The NHS just gave it a 60-second injection to lock in patients before biosimilars arrive. The race is on.
May 9, 2026
FDA approves Opdivo Qvantig, a new subcutaneous immunotherapy option for cancer treatment
In a significant advancement for oncology care, the U.S. Food and Drug Administration (FDA) has approved Opdivo Qvantig…
December 30, 2024